CONFÉRENCE SUR LA PRATIQUE CLINIQUE DE L’ACIO-CANO Élaboration et mise en place par ActionCancer Manitoba d’un programme d’administration d’immunoglobuline par voie sous-cutanée

Erin Streu

Abstract


La conférence de l’ACIO-CANO sur la pratique clinique met en évidence un programme novateur des soins infirmiers qui améliore les soins aux patients et la qualité de vie des personnes aux prises avec le cancer. C’est un privilège de pouvoir communiquer au personnel infirmier en oncologie du Canada les détails relatifs au programme d’administration d’immunoglobulines par voie sous-cutanée d’ActionCancer Manitoba (ACMB). Non seulement notre programme offre-t-il aux patients diagnostiqués d’un cancer la possibilité de recevoir leur traitement de soutien par immunoglobulines à domicile, mais il donne aussi l’occasion au personnel infirmier de faire participer les patients en les amenant à prendre leurs soins en charge. Ce programme montre à quel point une possibilité d’innover et de mettre en place un changement à la fois axé sur le patient, entrepris par le personnel infirmier et d’une importance appréciable a mené à d’importants résultats positifs pour nos patients et notre établissement. 


Full Text:

PDF

References


CCMB Practice Guideline. (2015). Disease Management Consensus Recommendations for the Management of Chronic Lymphocytic Leukemia. Sur Internet : www.cancercare.mb.ca.

CLL Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. (1988). Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. Essai clinique aléatoire, contrôlé. NEJM, 319(14), 902.

Compagno, N., Malipiero, G., Cinetto, F., et Agostini, C. (2014). Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Frontiers in Immunology, 5(626), 1–6.

Ducruet, T., Levasseur, M.C., Des Roche, A., Kafal, A., Dicaire, R. et Haddad, E. (2013). Pharmacoeconomic advantages of subcutaneous versus intravenous treatment in a Canadian pediatric center. Journal of Allergy and Clinical Immunology, 131, 585–590.

Freeman, J.A., Crassini, K.R., Best, O.G., Forsyth, C.J., Mackinlay, Han et al. (2013). Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic leukemia. Leukemia Lymphoma, 54(1), 99–104.

Gardulf, A., Hammarstrom, L. et Smith, C.I. (1991). Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet, 338, 162–166.

Gardulf, A., Nicolay, U., Math, D., Asensio, O., Bernatowska, E., Bock, A. et al. (2004). Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. Journal of Allergy and Clinical Immunology, 114, 936–942.

Gerth, W.C., Betschel, S.D. et Zbrozek, A.S. (2014). Implications to payers of switch from hospitalbased intravenous immunoglobulin to homebased subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada. Allergy, Asthma and Clinical Immunology, 10(23).

Greer, J.P., Arber, D.A., Glader, B., List, A., Means, R.T., Paraskevas, F. et Rodgers, G. (Éd.). (2014). Wintrobe’s clinical hematology (13e éd.). Philadelphie, PA. Lippincott Williams and Wilkins.

Jolles, S. et Sleasman, J.W. (2011). Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: A practical approach. Advances in Therapy, 28(7), 521–533.

Martin, A., Lavie, L., Goetghebeur, M., Schellenberg, R. (2012). Economic benefit of subcutaneous rapid push versus intravenous infusion therapy in adult patients with primary immune deficiency. Allergy, Asthma and Clinical Immunology, 8(suppl. 1) A20.

Misbah, S., Sturzenegger, M.H., Borte, M., Shapiro, R.S., Wasserman, R.L., Berger, M. et Ochs, H.D. (2009). Subcutaneous immunoglobulin: Opportunities and outlook. Clinical and Experimental Immunology, 158(suppl. 1), 5159.

Morra, E, Nosari, A. et Montillo, M. (1999). Infectious complications in chronic lymphocytic leukemia. Hematology and Cell Therapy. 41, 145–151.

Morrison, V. (2010). Infectious complications of chronic lymphocytic leukemia: Pathogenesis, spectrum of infection, preventive approaches. Best Practice and Research Clinical Hematology, 23(1), 145153.

Navarro, R.P. (2012). Considerations for the Optimal Use of Immunoglobulins. American Journal of Managed Care, 18, 4s.

Nicolay, U., Kiessling, P., Berger, M., Gupta, S., Yel, L., Roifman, C. et al. (2006). Healthrelated quality of life and treatment satisfaction in North American patients with primary immunedeficiency disease receiving subcutaneous IgG self-infusion at home. Journal of Clinical Immunology, 26(1), 65–72.

Orange, J.S., Belohradsky, B.H., Berger, M., Borte, M., Hagan, J., Jolles, S. et al. (2012). Evaluation of correlation between d se and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clinical and Experimental Immunology, 169, 172181.

Oscier, D., Dearden, C., Eren, E., Erem, E., Fegan, C., Follows, G. et al. (2012). Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukemia. British Journal of Hematology, 159, 541–564.

Parikh, S.A., Leis, J.F., Chaffee, K.G., Call, T.G., Hanson, C.A., Ding, W. et al. (2015). Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates and outcomes. Cancer, 121(17), 2883–2891.

Shelton, B., Griffin, J.M. et Goldman, F.D. (2006). Immune globulin IV therapy: Optimizing care of patients in the oncology setting. Oncology Nursing Forum, 33(5), 911–921.

Skoda-Smith, S., Torgerson, T.R. et Ochs, H.D. (2010). Subcutaneous immunoglobulin replacement in the treatment of patients with primary immunodeficiency. Journal of Therapeutics and Clinical Risk Management, 2(6), 1–10.


Refbacks

  • There are currently no refbacks.


Bookmark and Share